Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04520672

Circulating Tumor Cells (CTC) in Cancer

This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cancer Neoplasm Metastasis Neoplasms Neoplastic Cells, Circulating Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Basel, Basel, Switzerland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult cancer patients
  • All patients with histology-based proved diagnosis of cancer, all stages and subtypes can be included. Precancerous lesions cannot be included.
  • All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, sarcoma
  • Written pathology report must be available.
  • Written informed consent.

Exclusion criteria

  • No written informed consent.
  • No proved diagnosis of malignancy by pathology report.
  • Patients with the diagnosis of blood cancer

Treatment and study plan

Blood Samples

Other

Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.

Samples from tumor draining vessels

Other

In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.

Primary outcomes

  1. Overall survival (OS) in heterogeneous cancer population

    Time frame: Screening (Visit 1) until the date of death (assessed up to 240 months)

    overall survival (OS) in heterogeneous cancer population

  2. Change in total number of isolated CTCs

    Time frame: Through study completion, an average of 20 years

    Change in total number of isolated CTCs

Secondary outcomes

  1. Progression free survival (PFS)

    Time frame: Through study completion, an average of 20 years

    progression free survival (PFS) in the different cancer cohorts with different treatment regimes

Other outcomes

  1. Change in circulating tumor DNA (ctDNA) from blood samples

    Time frame: Through study completion, an average of 20 years

    Change in circulating tumor DNA (ctDNA) from blood samples

Study contacts

Contact information is provided by the study sponsor or research team.

Marcus Vetter, PD Dr. med.

CONTACT

[email protected]

+41 61 925 27 15

Nicola Aceto, Prof. Dr. med.

CONTACT

[email protected]

+41 44 633 40 23

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Important dates

Study start
2020
Primary completion
2030
Study completion
2030
First posted
Aug 20, 2020
Registry last updated
Mar 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.